A phase III trial has been stopped early after promising results for Avastin and Tarceva combined as first-line maintenance treatment …
GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK …
Most of us recognise that personal training and development is an essential requirement for successful career advancement, but for many …
How did you find your way into your role? This was really through what I would describe as the 'traditional' …
Bayer Schering Pharma has begun phase III trials of riociguat for treatment of two life-threatening conditions. Two trials will investigate …
Patients who have a hip replacements or varicose vein surgery on the NHS will be among the first patients to …
Sanofi-Aventis's new chief executive Chris Viehbacher has presented his vision to renew the company, which will include greater investment in …
The European Commission says Sanofi-Aventis can go ahead with its planned acquisition of Czech generics company Zentiva. The Commission had …
Novartis has weathered the financial downturn and delivered a strong performance for 2008. Overall group sales were boosted by 9% …
Health Secretary Alan Johnson has been appointed the chair of the Ministerial Industry Strategy Group (MISG) and business secretary Lord …
In retrospect, Pfizer's move to buy another major pharmaceutical company was inevitable. Like its peers, Pfizer has been energetically restructuring …
Pfizer has announced plans to disclose payments to healthcare professionals involved in clinical trials. The company will publicly declare all …
Roche delivered solid performance in 2008, but was unable to shake off the negative effect of a strong Swiss franc. …
Roche has launched a renewed bid to buy out Genentech, making a 'hostile' bid for the company by appealing directly …
GlaxoSmithKline has expanded its restructuring plans and will make widespread job cuts in a bid to cut costs throughout its …
Indian pharmaceutical company Piramal has denied that it ready to sell up to one of the global giants of the …
Schering-Plough is to invest around $30 million in its early drug discovery work in Scotland. The company is investing a …
Another week, and another swathe of job losses across the pharmaceutical sector, with sales and back office staff once again …
Pharma has always been a highly profitable industry, and has historically been among the best performing industrial sectors in terms …